Codagenix lands $20 mln Series B

Farmingdale, New York-based Codagenix Inc, a developer of prophylactic vaccines and oncolytic virus therapies, has raised $20 million in Series B funding.

Farmingdale, New York-based Codagenix Inc, a developer of prophylactic vaccines and oncolytic virus therapies, has raised $20 million in Series B funding. Adjuvant Capital led the round with participation from Euclidean Capital and Topspin Partners.

Source: Press Release